Stock Events

Stock Events

Oxurion NV 

0
0
+€0.00+0% 00:00 Today

Statistics

Day High
-
Day Low
-
52W High
-
52W Low
-
Volume
-
Avg. Volume
-
Mkt Cap
0
P/E Ratio
-
Dividend Yield
-
Dividend
-

Upcoming

Earnings

Sep 3Expected
Q1 2023
Q2 2026
-3,532.45
-2,687.97
-1,843.48
-999
Expected EPS
N/A
Actual EPS
N/A

Financials

-671.71%Profit Margin
Unprofitable
2020
2021
2022
2023
2024
2025
555,000Revenue
-3.73MNet Income

People Also Follow

This list is based on the watchlists of people on Stock Events who follow TG40.MU. It's not an investment recommendation.
Apple
4
AAPL
Anheuser-Busch InBev SA/NV
4
ABI.BR
Bpost. / N.V
4
BPOST.BR
Amazon
3
AMZN

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
Regeneron Pharmaceuticals
REGN
Mkt Cap95.99B
Regeneron Pharmaceuticals competes in the ophthalmology space, particularly in treatments for eye diseases, similar to Oxurion's focus on diabetic eye disease treatments.
Novartis
NVS
Mkt Cap303.67B
Novartis offers a range of treatments for eye conditions, including macular degeneration and diabetic retinopathy, directly competing with Oxurion's product offerings.
Roche
RHHBY
Mkt Cap334.28B
Roche, through its Genentech division, develops therapies for ophthalmic diseases, competing in the same market as Oxurion, especially in the area of diabetic eye disease.
Bausch Health Companies
BHC
Mkt Cap3.07B
Bausch Health Companies, through its Bausch + Lomb segment, provides products for eye health, including treatments for retinal diseases, making it a competitor.
Abbvie
ABBV
Mkt Cap521.11B
AbbVie, having acquired Allergan, competes in the eye care market, particularly in treatments for retinal diseases, similar to Oxurion's focus.
Biogen
BIIB
Mkt Cap37.49B
Biogen has ventured into ophthalmology, including treatments for retinal diseases, positioning it as a competitor in the eye disease treatment market.
The Nightview Fund NITE
NITE
Mkt Cap0
Nightstar Therapeutics, acquired by Biogen, focuses on gene therapies for inherited retinal disorders, competing in the advanced treatment segment of the market.

About

Oxurion N.V. is a biopharmaceutical enterprise dedicated to the research, development, and marketing of innovative treatments for ocular diseases, operating both within Belgium and across international markets. Its primary commercialized therapy is JETREA, prescribed for vitreomacular adhesion and vitreomacular traction. Beyond this, Oxurion's clinical pipeline includes two promising compounds in Phase II trials for diabetic macular edema (DME): THR-149, which functions as a plasma kallikrein inhibitor, and THR-687, an integrin antagonist. The company also fosters collaborative relationships with Bicycle Therapeutics, INC Research, and Galapagos NV. Founded in 1991, this Leuven, Belgium-headquartered firm adopted its current name, Oxurion N.V., in September 2018, having previously operated as ThromboGenics NV.
Show More
CEO
Pascal Ghoson
Employees
11
Country
Belgium
ISIN
BE0974487192
WKN
000A40H8H

Listings

MU
DE
TG40.MU
STU
DE
TG40.STU
F
DE
TG40.F
STU
DE
TG4.STU

0 Comments

Share your thoughts

FAQs

What is Oxurion NV stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on Boerse Muenchen exchange Oxurion NV stocks are traded under the ticker TG40.MU.
When is the next Oxurion NV earnings date?▼
Oxurion NV is going to release the next earnings report on March 3, 2027.
What is Oxurion NV revenue for the last year?▼
Oxurion NV revenue for the last year amounts to 555,000 EUR.
What is Oxurion NV net income for the last year?▼
TG40.MU net income for the last year is -3.73M EUR.
How many employees does Oxurion NV have?▼
As of November 4, 2026, the company has 11 employees.
In which sector is Oxurion NV located?▼
Oxurion NV operates in the Health & Wellness sector.
When did Oxurion NV complete a stock split?▼
Oxurion NV has not had any recent stock splits.
Where is Oxurion NV headquartered?▼
Oxurion NV is headquartered in Leuven, Belgium.